This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
326
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Proportion of patients with at least 75% improvement in PASI from baseline (PASI75) at Week 16.
Time frame: Baseline to week 16
Proportion of patients with "Clear" or "Almost clear" on PGA at Week 16.
Time frame: Baseline to week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Investigative Site 1006
Feldkirch, Austria
Clinical Investigative Site 1002
Graz, Austria
Clinical Investigative Site 1004
Sankt Pölten, Austria
Clinical Investigative Site 1007
Vienna, Austria
Clinical Investigative Site 1001
Vienna, Austria
Clinical Investigative Site 1103
Brussels, Belgium
Clinical Investigative Site 1102
Edegem, Belgium
Clinical Investigative Site 1101
Liège, Belgium
Clinical Investigative Site 1205
Pleven, Bulgaria
Clinical Investigative Site 1204
Plovdiv, Bulgaria
...and 57 more locations